Effective management of ocular allergies often requires a comprehensive approach that addresses removing the allergen from the ocular mucosa.
Rinsada is designed to assist clinicians by providing controlled eyelid irrigation to the conjunctival fornix and palpebral conjunctiva.
Clinical studies have shown a 70% reduction in matrix metalloproteinase-9 (MMP-9) – a key inflammatory marker, in some patients for up to 12 weeks.1 For allergic rhinitis patients, the current standard of care involves nasal sinus rinsing to remove allergens from the nasal mucosa. Rinsada applies this approach to the ocular surface and has shown that patients who are treated with Rinsada plus topical olopatadine have an immediate symptom improvement superior to topical olopatadine alone.2 This interventional approach to ocular allergies targets multiple points along the allergic cascade and provides long-lasting symptom relief.
Visit: goodopticalservices.com.au
References
- Mayer N, et al. Adv Ophthalmol Pract Res. 2024. doi: 10.1016/j.aopr.2024.05.002.
- Rinsada data on file and in submission for presentation at American Academy of Optometry Annual Meeting 2026.
